Skip to content

Comparison effects of mannitol and hypertonic saline on coagulation in vitro: a randomized, blinded trial.

Comparison effects of 20 % mannitol and 3 % hypertonic saline on coagulation in vitro in healthy volunteers: a randomized, blinded trial.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615000005550
Enrollment
15
Registered
2015-01-07
Start date
2015-04-10
Completion date
2015-06-05
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Twenty ml blood samples were obtained from an antecubital vein using an 18 G venous cannula (VasofixTM, B. Braun, Melsungen, Germany) from each participant. Four ml blood sample was seperated for each group. In each group 2 ml blood were collected into polypropylene tubes (Vacuette, Greiner Bio-one, Austria) containing 3.2% buffered citrate, giving a volume ratio of 1:10 for ROTEM analysis and 2 ml blood were collected into EDTA tubes containing 1.2 mg anhydrous EDTA per 1ml blood (Vacuette, Greiner Bio-one, Austria) for hemogram analysis. Sensitive electronic pipette was used for make mixtures. Immediately after sampling all blood samples were diluted with the test solutions. Thereafter, within 1 hours after blood withdrawal, thromboelastometry coagulation analysis will made in random order from the diluted samples and a control of undiluted blood. Automatically measured thromboelastometry parameters of blood coagulation will be recorded. This parameters are Clotting time (CT), Clot formation time (CFT) and Maximum clot firmness (MCF). (We will record each CT,CFT and MCF measurements at INTEM, EXTEM and FIBTEM) We also will record hemoglobin and platelet value of each sample. In present study there are five arm. Arm 1: Control group. Arm 2 : 7% Mannitol group. Arm 3: 7% hypertonic saline group. Arm 4: 6% Mannitol - 8%HES group. Arm 5: 6% Hypertonic saline - 8%HES group.

Interventions

We will take 20 ml blood ( 5 tube of 4ml) an antecubital vein from healthy volunteers for study.. Four ml blood sample was seperated for each group. In each group 2 ml blood were collected into polypropylene tubes (Vacuette, Greiner Bio-one, Austria) containing 3.2% buffered citrate, giving a volume ratio of 1:10 for ROTEM analysis and 2 ml blood were collected into EDTA tubes containing 1.2 mg anhydrous EDTA per 1ml blood (Vacuette, Greiner Bio-one, Austria) for hemogram analysis.Immediately a

We will take 20 ml blood ( 5 tube of 4ml) an antecubital vein from healthy volunteers for study.. Four ml blood sample was seperated for each group. In each group 2 ml blood were collected into polypropylene tubes (Vacuette, Greiner Bio-one, Austria) containing 3.2% buffered citrate, giving a volume ratio of 1:10 for ROTEM analysis and 2 ml blood were collected into EDTA tubes containing 1.2 mg anhydrous EDTA per 1ml blood (Vacuette, Greiner Bio-one, Austria) for hemogram analysis.Immediately after sampling all blood samples were diluted with the test solutions.Thereafter, within 2 hours after blood withdrawal, thromboelastometry coagulation analysis (ROTEM; Pentapharm Co., Munich, Germany) was made in random order for all samples. The coagulation process will initiate by recalcification (Star-TEM; Pentapharm Co., Munich,Germany) and activation with tissue factor EXTEM and INTEM for monitoring the extrinsic system, and intrinsec system . In the FIBTEM assay (fib-TEM, Pentapharm Co.) a plateletinhibitor (GPIIb/IIIa platelet receptor antagonist abciximab) together with cytochalasin D was added to assess the contribution of fibrinogen to clot strength, and EXTEM analysis was carried out. Automatically measured thromboelastometry parameters of blood coagulation will be recorded. This parameters are Clotting time (CT), Clot formation time (CFT) and Maximum clot firmness (MCF). (We will record each CT,CFT and MCF measurements at INTEM, EXTEM and FIBTEM) We also will record hemoglobin and platelet value of each sample. In present study there are five arm. Arm 1: Control group. Sample contain 2 ml pure blood. We will make thromboelastometry coagulation analysis this sample. Arm 2 : 7% Mannitol group. Sample contain: 1.86ml blood and 0.14 ml 20% mannitol. We will make thromboelastometry coagulation analysis this sample. Arm 3: 7% hypertonic saline group. Sample contain 1.86 ml blood and 0.14 ml 3%NACL. We will make thromboelastometry coagulation analysis this sample. Arm 4: 6% Mannitol - 8%HES group. Sample contain 1.72 ml blood, 0.12 ml 20% mannitol and 0.16 ml Hydroxyethyl Starch 130/0.4. We will make thromboelastometry coagulation analysis this sample. Arm 5: 6% Hypertonic saline - 8%HES group. contain 1.72 ml blood, 0.12 ml 3%NACL and 0.16 ml Hydroxyethyl Starch 130/0.4. We will make thromboelastometry coagulation analysis this sample.

Sponsors

istanbul university
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Diagnosis
Masking
Blinded (masking used) (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1-Aged 18 - to 65 years old 2- no bleeding diathesis. 3-no liver failure. 4- no renal failure. 5-No blood transfusion within 1 month. 6- No any medication within 1 month. 7- normal hemoglobin and platelet values 8- No alcohol use within 1 week

Exclusion criteria

the thromboelastometry value measured in the control sample is outside the normal values.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026